{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:42:14Z","timestamp":1787794934196,"version":"build-2784847793"},"reference-count":56,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100000320","name":"Alzheimer\u2019s Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,2,18]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To test whether the use of potentially inappropriate central nervous system acting medications, proton pump inhibitors (PPIs) or polypharmacy are associated with mortality in cognitively impaired older adults and whether frailer people are at greater risk of harm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A cohort study nested within the Cognitive Function and Ageing Study II, a population representative cohort study of the older population in Cambridgeshire, Nottingham and Newcastle, UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 1154 cognitively impaired participants, aged 65 years or older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Any use of antipsychotics, antidepressants, other anticholinergic medication, benzodiazepines or PPIs, polypharmacy (5\u20139) and hyperpolypharmacy (\u226510 reported medications) were ascertained at baseline. Frailty was assessed using the Fried criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome<\/jats:title>\n                    <jats:p>Mortality up to 8 years follow-up. HRs associated with potentially inappropriate medication (PIM), frailty and their interaction were estimated adjusting for covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within the sample, 44% were taking one or more PIM. Apart from antipsychotics (adjusted HR=3.24, 95% CI 1.83 to 5.73), use of specific PIM was not associated with greater subsequent mortality. Polypharmacy (HR=1.17, 95% CI 0.95 to 1.45) and hyperpolypharmacy were associated with mortality (HR=1.60, 95% CI 1.16 to 2.22). Being frail (HR=1.90, 95% CI 1.32 to 2.72) or prefrail (HR=1.56, 95% CI 1.10 to 2.20) was associated with increased mortality. There was some evidence that the HR for polypharmacy on mortality was lower among frailer individuals, but the overall polypharmacy by frailty interaction was not statistically significant (p=0.102).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For those with cognitive impairment, greater concern should be afforded to the number of medications than the prescription of specific classes. Frailer individuals may have a lower relative risk of mortality associated with polypharmacy than less frail individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-026171","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T06:25:46Z","timestamp":1557901546000},"page":"e026171","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":62,"title":["How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study"],"prefix":"10.1136","volume":"9","author":[{"given":"Bryony","family":"Porter","sequence":"first","affiliation":[{"name":"School of Health Sciences, University of East Anglia, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Arthur","sequence":"additional","affiliation":[{"name":"School of Health Sciences, University of East Anglia, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M","family":"Savva","sequence":"additional","affiliation":[{"name":"School of Health Sciences, University of East Anglia, Norwich, UK"},{"name":"Quadram Institute Bioscience, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"2025121509342336000_9.5.e026171.1","unstructured":"Alzheimer\u2019s Society. Dementia UK: update. 2014 https:\/\/www.alzheimers.org.uk\/about-us\/policy-and-influencing\/dementia-uk-report"},{"key":"2025121509342336000_9.5.e026171.2","unstructured":"All-Party Parliamentary Group. Dementia rarely travels alone, 2016. https:\/\/www.alzheimers.org.uk\/appg"},{"key":"2025121509342336000_9.5.e026171.3","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13153"},{"key":"2025121509342336000_9.5.e026171.4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jamda.2017.02.009","article-title":"Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study","volume":"18","author":"Veronese","year":"2017","journal-title":"J Am Med Dir Assoc"},{"key":"2025121509342336000_9.5.e026171.5","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"2025121509342336000_9.5.e026171.6","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050051"},{"key":"2025121509342336000_9.5.e026171.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62167-9"},{"key":"2025121509342336000_9.5.e026171.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gerona\/glx185","article-title":"Frailty, hospitalization, and mortality in residential aged care","volume":"73","author":"Theou","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025121509342336000_9.5.e026171.9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/gerona\/glx214","article-title":"Delirium, frailty, and mortality: interactions in a prospective study of hospitalized older people","volume":"73","author":"Dani","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025121509342336000_9.5.e026171.10","unstructured":"NHS England. Updated guidance on supporting routine frailty identification and frailty care through the GP Contract 2017\/2018, 2017."},{"key":"2025121509342336000_9.5.e026171.11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jamda.2017.07.008","article-title":"Frailty, polypharmacy, and health outcomes in older adults: the\u00a0frailty and dependence in albacete study","volume":"19","author":"Bonaga","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"2025121509342336000_9.5.e026171.12","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0287-4"},{"key":"2025121509342336000_9.5.e026171.13","doi-asserted-by":"crossref","first-page":"68-74","DOI":"10.1093\/ageing\/afx147","article-title":"Potentially inappropriate medication among people with dementia in eight European countries","volume":"47","author":"Renom-Guiteras","year":"2018","journal-title":"Age Ageing"},{"key":"2025121509342336000_9.5.e026171.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1543-5946(10)80005-4"},{"key":"2025121509342336000_9.5.e026171.15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-14-72"},{"key":"2025121509342336000_9.5.e026171.16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3233\/JAD-151177","article-title":"Potentially inappropriate prescribing among people with dementia in primary care: a retrospective cross-sectional study using the enhanced prescribing database","volume":"52","author":"Barry","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2025121509342336000_9.5.e026171.17","first-page":"2227","article-title":"American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults","volume":"11","author":"Fick","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"2025121509342336000_9.5.e026171.18","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu145"},{"key":"2025121509342336000_9.5.e026171.19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","article-title":"Adverse effects associated with proton pump inhibitors","volume":"176","author":"Schoenfeld","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121509342336000_9.5.e026171.20","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.092129"},{"key":"2025121509342336000_9.5.e026171.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304738"},{"key":"2025121509342336000_9.5.e026171.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010146"},{"key":"2025121509342336000_9.5.e026171.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(03)00088-4"},{"key":"2025121509342336000_9.5.e026171.24","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.108"},{"key":"2025121509342336000_9.5.e026171.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2947"},{"key":"2025121509342336000_9.5.e026171.26","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.113"},{"key":"2025121509342336000_9.5.e026171.27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pds.4043","article-title":"Proton pump inhibitor prescribing patterns in the UK: a primary care database study","volume":"25","author":"Othman","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121509342336000_9.5.e026171.28","unstructured":"British National Formulary. Antipsychotic drugs. 2011 https:\/\/bnf.nice.org.uk\/drug-class\/antipsychotic-drugs.html."},{"key":"2025121509342336000_9.5.e026171.29","doi-asserted-by":"crossref","unstructured":"McEvoy RD , Nyfort-Hansen KS . Sleep disorders in the elderly: the pros and cons of prescribing. In: Prescribing for Elderly Patients. Chichester, UK: John Wiley & Sons, Ltd:45\u201352.","DOI":"10.1002\/9780470017975.ch5"},{"key":"2025121509342336000_9.5.e026171.30","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65 Suppl 2","author":"Alexopoulos","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2025121509342336000_9.5.e026171.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38623.768588.47"},{"key":"2025121509342336000_9.5.e026171.32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/014107680009300903","article-title":"Anticholinergic side-effects of drugs in elderly people","volume":"93","author":"Mintzer","year":"2000","journal-title":"J R Soc Med"},{"key":"2025121509342336000_9.5.e026171.33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40266-017-0475-5","article-title":"Risk of mortality associated with anticholinergic use in elderly nursing home residents with depression","volume":"34","author":"Chatterjee","year":"2017","journal-title":"Drugs Aging"},{"key":"2025121509342336000_9.5.e026171.34","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1522-0"},{"key":"2025121509342336000_9.5.e026171.35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/17425255.2017.1325873","article-title":"Pharmacokinetic and pharmacodynamic alterations in older people with dementia","volume":"13","author":"Reeve","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025121509342336000_9.5.e026171.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61092-7"},{"key":"2025121509342336000_9.5.e026171.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61570-6"},{"key":"2025121509342336000_9.5.e026171.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01820.x"},{"key":"2025121509342336000_9.5.e026171.39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2532.1994.1130177.x"},{"key":"2025121509342336000_9.5.e026171.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122246"},{"key":"2025121509342336000_9.5.e026171.41","doi-asserted-by":"publisher","DOI":"10.2217\/1745509X.4.3.311"},{"key":"2025121509342336000_9.5.e026171.42","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3772"},{"key":"2025121509342336000_9.5.e026171.43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2016.03.007","article-title":"Frailty measurement in research and clinical practice: A review","volume":"31","author":"Dent","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2025121509342336000_9.5.e026171.44","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gls190"},{"key":"2025121509342336000_9.5.e026171.45","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu148"},{"key":"2025121509342336000_9.5.e026171.46","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/59.11.1207"},{"key":"2025121509342336000_9.5.e026171.47","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/69.1.239"},{"key":"2025121509342336000_9.5.e026171.48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1227"},{"key":"2025121509342336000_9.5.e026171.49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-170265","article-title":"Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics","volume":"60","author":"Cross","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2025121509342336000_9.5.e026171.50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1315"},{"key":"2025121509342336000_9.5.e026171.51","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-009-0426-1"},{"key":"2025121509342336000_9.5.e026171.52","doi-asserted-by":"publisher","DOI":"10.3109\/13814788.2014.905535"},{"key":"2025121509342336000_9.5.e026171.53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","article-title":"Adverse effects associated with proton pump inhibitors","volume":"176","author":"Schoenfeld","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121509342336000_9.5.e026171.54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jgs.13877","article-title":"Effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: the concord health and ageing in men project cohort study","volume":"64","author":"Jamsen","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"2025121509342336000_9.5.e026171.55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.04054.x"},{"key":"2025121509342336000_9.5.e026171.56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ageing\/afx162","article-title":"Frailty index as a predictor of mortality: a systematic review and meta-analysis","volume":"47","author":"Kojima","year":"2018","journal-title":"Age Ageing"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-026171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:34:31Z","timestamp":1765820071000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-026171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,14]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bmjopen-2018-026171"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-026171","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}